Wedbush PacGrow Life Sciences Hosts Management Access Conference, Offers Investors Industry Insight

• 

New York, NY and Los Angeles, CA (PRWEB) August 13, 2013

Wedbush Securities, one of the nation’s leading broker-dealers and award-winning equity research firms, will host its annual Wedbush PacGrow Life Sciences Management Access Conference in New York from August 13 - 14, 2013. The conference connects institutional investors with management teams and senior executives from more than 75 prominent public and private companies across sectors including biotechnology, medical devices, emerging pharmaceuticals, healthcare services, managed care, medical diagnostics and life sciences tools.

In addition to various company presentations moderated by some of the firm’s leading research analysts, the Wedbush PacGrow team will host a panel discussion each day offering a deeper dive into trending industry topics. On Tuesday, August 13, PTC Therapeutics, Prosensa, Sarepta Therapeutics and Summit PLC will participate in a discussion on “Leaders in DMD and Rare Diseases.” Additionally, Ariosa Diagnostics, CellScape, Illumina, KellBenX, Natera and Sequenom will be joined by several physicians to lead a discussion on “Pre-natal Pioneers” on Wednesday, August 14.

“The Wedbush Equity Research team is proud to host its annual Life Sciences conference which uniquely highlights performance trends that support the investment community in their decision making processes,” said Mark Benson, Director of Research, Wedbush Securities. He continued by saying that the conference “offers an opportunity for our valued client base to connect with senior management from leading Life Sciences firms and receive critical industry insights.”

The following companies are scheduled to present at the Wedbush PacGrow Life Sciences Management Access Conference: Alexza, Algeta, Amicus Therapeutics, Anacor Pharmaceuticals, Ariosa Diagnostics, Avanir Pharmaceuticals, AxoGen, Biodel, Cadence Pharmaceuticals, Bluebird Bio, Cara Therapeutics, Cardica, Catabasis Pharmaceuticals, CellScape, Cepheid, Cerus, Chelsea Therapeutics, Civitas Therapeutics, CONMED Corporation, Coronado Biosciences, Curis, Delcath Systems, diaDexus, Durata Therapeutics, EndoStim, Emergent BioSolutions, Epizyme, Endocyte, Forma Therapeutics, Genocea, Gentium S.p.A., Good Start Genetics, GTx, Inc., Illumina, ImmunoGen, Insmed, Intercept Pharmaceuticals, IRIDEX, KellBenX, Kindred Bio, Lexicon Pharmaceuticals, Medivation, MEI Pharma, Metabolon, Natera, Novavax, NPS Pharmaceuticals, Ohr Pharmaceutical, Omeros Corp., OncoGenex Pharmaceuticals, Oncolytics Biotech, Oncothyreon, OvaScience, Pacira Pharmaceuticals, Palatin Technologies, Peregrine Pharmaceuticals, Prosensa, Prothena Corporation, PTC Therapeutics, Receptos, Regado Biosciences, Relypsa, Sangamo BioSciences, Sarepta Therapeutics, Sequenom, SIGA Technologies, Spectral Diagnostics, Spectrum Pharmaceuticals, Stemline Therapeutics, Summit PLC, Sunesis Pharmaceuticals, Synageva Biopharma, Tekmira Pharmaceuticals, Ultragenyx, Verastem, Xencor, Xoma and Zalicus.

The Wedbush PacGrow Life Sciences Management Access Conference is by invitation only. Please contact the Wedbush Equity Research team at (213) 688-4529 for additional information.

# # #

About Wedbush Equity Research
Wedbush Equity Research offers in-depth and differentiated research coverage across the consumer, life sciences, technology and industrial growth sectors. The team, comprised of more than 25 publishing analysts, generates timely, insightful analyses and the firm’s award-winning Wedbush Best Ideas List - an actively monitored compilation of stock ideas identifying outperformance trends over the forward 6 to 12 month period. Wedbush Equity Research has repeatedly been named a “Top Stock Picking Firm” by Barron’s and Zacks Investment Research, and consistently ranks among the industry’s leading performance surveys including StarMine’s “Analyst Performance Survey,” Financial Times’ “Top Analysts,” Institutional Investor’s “Rising Stars of Wall Street Research” and The Wall Street Journal’s “Best of the Street.”

About Wedbush Securities
Founded in 1955, Wedbush Securities is a leading investment firm that provides brokerage, clearing, investment banking, equity research, public finance, fixed income sales and trading, and asset management to individual, institutional and issuing clients. Headquartered in Los Angeles, with over registered 100 offices, the firm focuses on relentless service, client financial safety, continuity, and advanced technology. Wedbush Securities is the largest subsidiary of holding company WEDBUSH, Inc., which also includes affiliated firms Wedbush Bank, Wedbush Capital Partners, Wedbush Opportunity Partners, Wedbush Asset Management and Lime Brokerage LLC. Follow us on Twitter @Wedbush.

PDF Print